Home Molecular Dx Liquid Biopsies

Liquid Biopsies

Latest
illustration DNA And Blood cell Futuristic digital design,Abstract background for Business Science and technology
Liquid Biopsies

New Nanopore Technique Could Improve cfDNA Analysis

Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]
Liquid Biopsies

Novel Biomarker Could Aid Development of Drugs for Age-Related Disorders

Genetic research, conceptual illustration
Liquid Biopsies

Exact Sciences to Acquire Ashion Analytics from TGen

Inivata and Thermo Fisher Scientific are collaborating with Genomics England to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease management and patient outcomes. [Source: © Alex Tihonov/Fotolia]
Liquid Biopsies

Resolution Bioscience, Mirati Therapeutics Ink CDx Deal

The combination of Bristol-Myers Squibb (BMS)'s marketed cancer immunotherapies Opdivo (nivolumab) plus a low dose of Yervoy (ipilimumab) showed durable clinical benefit in a Phase II trial as a first-line treatment in patients with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
Liquid Biopsies

Guardant Throws Hat in Early Cancer Detection Ring with CRC Test

brain tumor
Liquid Biopsies

Cerebrospinal Fluid Samples Provide Accurate Picture of Medulloblastoma

Liquid Biopsies

Exact Sciences Eyes Cancer Dx Leadership with Up to $2.5B in...

Glioma - brain tumor
Liquid Biopsies

Glioma Diagnosis, Monitoring Potentially Improved by Enhanced Liquid Biopsy Test

Faecali bacterium
Liquid Biopsies

Prime Time for the Microbiome

ersonal Genome Diagnostics (PGDx) said today that its 500+ gene pan-cancer tumor profiling tissue assay is being used by Merck & Co. in a Phase II clinical trial designed to assess patient response to a dual biomarker-directed precision oncology combination therapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC).
Liquid Biopsies

Biocept’s NSCLC Liquid Biopsy Gains Coverage from Insurer Highmark

Load more

New Products

View More
Load more
Copyright © 2020 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up